Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (121-130 of 265) with videos related to

Pageof 27
Sort By:
Dermatology and Therapy|February 1, 2024
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)Kristian Reich, Luca Bianchi, Abdallah Khemis, et al.
Experimental Dermatology|June 5, 2023
Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW studyJames Krueger, Richard G Langley, Simon Nigen, et al.
Lancet (London, England)|August 13, 2019
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialKristian Reich, April W Armstrong, Richard G Langley, et al.
The Journal of Dermatological Treatment|October 21, 2016
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Kristian Reich, Craig Leonardi, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
Arthritis and Rheumatism|May 29, 2007
TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk alleleKristian Reich, Ulrike Hüffmeier, Inke R König, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
The British Journal of Dermatology|February 10, 2023
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3Kristian Reich, Eric Simpson, Andreas Wollenberg, et al.
The Journal of Investigative Dermatology|September 19, 2008
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritisUlrike Hüffmeier, Jesús Lascorz, Beate Böhm, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pageof 27

Showing results (121-130 of 265) with videos related to

Sort By:
Pageof 27
Dermatology and Therapy|February 1, 2024
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)Kristian Reich, Luca Bianchi, Abdallah Khemis, et al.
Experimental Dermatology|June 5, 2023
Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW studyJames Krueger, Richard G Langley, Simon Nigen, et al.
Lancet (London, England)|August 13, 2019
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialKristian Reich, April W Armstrong, Richard G Langley, et al.
The Journal of Dermatological Treatment|October 21, 2016
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Kristian Reich, Craig Leonardi, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
Arthritis and Rheumatism|May 29, 2007
TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk alleleKristian Reich, Ulrike Hüffmeier, Inke R König, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
The British Journal of Dermatology|February 10, 2023
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3Kristian Reich, Eric Simpson, Andreas Wollenberg, et al.
The Journal of Investigative Dermatology|September 19, 2008
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritisUlrike Hüffmeier, Jesús Lascorz, Beate Böhm, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pageof 27